FINWIRES · TerminalLIVE
FINWIRES

NRW Holdings Secures AU$313 Million in New Contracts, Supporting Fiscal 2027 Growth Outlook, Euroz Hartleys Says

By

NRW Holdings (ASX:NWH) has strengthened its fiscal 2027 growth outlook with around AU$313 million in new contract awards, adding to its substantial order book and enhancing earnings visibility, Euroz Hartleys said in a Monday note.

The contracts include an engineering, procurement and construction award to Primero for Ramelius Resources' (ASX:RMS) Mt Magnet expansion project, along with optional works awarded by Main Roads Western Australia for the Tonkin Highway project.

Euroz Hartleys said the Mt Magnet award is significant for Primero and the company's minerals, energy and technology division, which posted AU$1.26 billion in fiscal 2026 revenue, an AU$800 million order book and AU$2.2 billion in active tenders.

The investment firm added that the Mt Magnet contract will ensure continuity of major minerals-processing work following the completion and ramp-down of Kalgoorlie Consolidated Gold Mines-related activity.

It expects further upside, driven by stronger activity in electrical, heating, ventilation and air conditioning services, resources and civil works, mining ramp-ups, and potential margin expansion.

Euroz Hartleys maintains its buy recommendation and AU$9.06 per share price target on NRW Holdings.

What else is happening in Asia?

Asia

Orora Chief Safety, Sustainability, Governance Officer to Step Down at End of Year

Orora (ASX:ORA) said Ann Stubbings plans to step down as chief safety, sustainability, and governance officer, effective Dec. 31, after more than 13 years with the packaging products firm, according to a Monday filing with the Australian bourse.In addition, Susannah Jobling Hodgens will be appointed as chief legal officer, the company said. Hodgens has worked with Orora for 13 years in senior legal and governance roles, most recently as general counsel and alternate company secretary.Orora shares gained nearly 1% in recent Monday trade.

ASX:ORA
Asia

Biokin Pharma Enrolls First Patient in Phase Three Trial for Breast Cancer Drug; Shares Up 4%

Sichuan Biokin Pharmaceutical (SHA:688506) enrolled the first subject for the third-phase clinical trial of biologic drug T-Bren for injection, according to a weekend filing with the Shanghai bourse.The trial evaluates T-Bren combined with pertuzumab versus standard chemotherapy in neoadjuvant treatment of HER2-positive breast cancer, according to a weekend filing with the Shanghai bourse.Shares of the pharmaceutical company rose 4% in recent trade.

SHA:688506
Asia

Market Chatter: Korea Exchange to Extend Trading Hours till 8PM

South Korea's main stock market, the Korea Exchange, will enable trading till 8 pm following the regular close at 3:30 pm from Monday, in its move toward 24-hour trading, Bloomberg News reported Sunday.This decision opens 2,400 Korea Composite Stock Price Index, or Kospi, and Kosdaq stocks for evening trades, which include short-selling. The move excludes exchange-traded funds, the report said.The Korea Exchange plans to introduce pre-market trading by the end of next year, it said.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

^KOSDAQKOSPI